Verrica’s Anticancer Efforts Kick Off With Promising Early Phase II BCC Data
In Handful Of Patients
The US firm’s oncolytic peptide candidate, VP-315, has shown tumor clearance in a Phase II basal cell carcinoma trial, marking a positive start for its plans to expand from non-malignant dermatology to skin cancer.
You may also be interested in...
Verrica’s Ycanth, a drug-device combination product containing a formulation of cantharidin, is approved by the FDA as the first treatment for molluscum, after three complete response letters.
Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.
Geron’s highly anticipated telomerase inhibitor has been given a user fee date by the US Food and Drug Administration next year and will also be subject to an advisory committee meeting, despite largely positive analyst sentiment on clinical results to date.